Literature DB >> 20713656

Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7.

Kyung-Ah Seo1, Soo Kyung Bae, Young-Kil Choi, Chang Soo Choi, Kwang-Hyeon Liu, Jae-Gook Shin.   

Abstract

Midazolam undergoes oxidative hydroxylation by CYP3A to its metabolites, which are excreted mainly as glucuronidated conjugates into the urine. In this study, we examined the glucuronidation of hydroxymidazolam in human liver microsomes (HLMs) and characterized the UDP-glucuronosyltransferases (UGTs) involved in 1'- and 4-hydroxymidazolam glucuronidation. Among the 12 UGT isoforms tested, the O- and N-glucuronidation of 1'-hydroxymidazolam was mediated by UGT2B4/2B7 and 1A4, respectively. In contrast, the glucuronidation of 4-hydroxymidazolam was mediated by UGT1A4. Consistent with these observations, the UGT1A4 inhibitor hecogenin and the UGT2B7 substrate diclofenac potently inhibited the N- and O-glucuronidation of 1'-hydroxymidazolam in HLMs, respectively. A correlation analysis of UGT enzymatic activity and the formation rate of glucuronide metabolites from 1'- and 4-hydroxymidazolam in 25 HLMs showed that hydroxymidazolam glucuronidation is correlated with UGT1A4-mediated lamotrigine glucuronidation and UGT2B7-mediated diclofenac glucuronidation activity. Taken together, these findings indicate that UGT1A4, 2B4, and 2B7 are major isoforms responsible for glucuronide conjugate formation from 1'- and 4-hydroxymidazolam, which are the two major oxidative metabolites of midazolam.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713656     DOI: 10.1124/dmd.110.035295

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.

Authors:  Nicolas Hohmann; Franziska Kocheise; Alexandra Carls; Jürgen Burhenne; Walter E Haefeli; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

2.  Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects.

Authors:  Feng Shao; Hongwen Zhang; Lijun Xie; Juan Chen; Sufeng Zhou; Jinsong Zhang; Jinru Lv; Weiwen Hao; Yunsu Ma; Yun Liu; Ning Ou; Wei Xiao
Journal:  Eur J Clin Pharmacol       Date:  2017-01-20       Impact factor: 2.953

3.  CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.

Authors:  Niladri Chattopadhyay; Tobias Kanacher; Manuela Casjens; Sebastian Frechen; Sandra Ligges; Torsten Zimmermann; Antje Rottmann; Bart Ploeger; Joachim Höchel; Marcus-Hillert Schultze-Mosgau
Journal:  Br J Clin Pharmacol       Date:  2018-10-11       Impact factor: 4.335

4.  Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?

Authors:  Linda G Franken; Anniek D Masman; Brenda C M de Winter; Frans P M Baar; Dick Tibboel; Teun van Gelder; Birgit C P Koch; Ron A A Mathot
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

5.  Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro.

Authors:  Saurav Howlader; Min-Jung Kim; M Rasheduzzaman Jony; Nguyen Phuoc Long; Yong-Soon Cho; Dong-Hyun Kim; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2022-10-03       Impact factor: 5.938

6.  Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation.

Authors:  Yazun Bashir Jarrar; Eun-Young Cha; Kyung-Ah Seo; Jong-Lyul Ghim; Hyo-Ji Kim; Dong-Hyun Kim; Su-Jun Lee; Jae-Gook Shin
Journal:  J Lipid Res       Date:  2014-09-23       Impact factor: 5.922

7.  Deoxyschizandrin, a naturally occurring lignan, is a specific probe substrate of human cytochrome P450 3A.

Authors:  Jingjing Wu; Yunfeng Cao; Yanyan Zhang; Yong Liu; James Y Hong; Liangliang Zhu; Guangbo Ge; Ling Yang
Journal:  Drug Metab Dispos       Date:  2013-10-16       Impact factor: 3.922

8.  Pharmacokinetic Drug Interaction Studies with Enzalutamide.

Authors:  Jacqueline A Gibbons; Michiel de Vries; Walter Krauwinkel; Yoshiaki Ohtsu; Jan Noukens; Jan-Stefan van der Walt; Roelof Mol; Joyce Mordenti; Taoufik Ouatas
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

9.  Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.

Authors:  J Yang; W M Atkins; N Isoherranen; M F Paine; K E Thummel
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

10.  Opposite Effects of Single-Dose and Multidose Administration of the Ethanol Extract of Danshen on CYP3A in Healthy Volunteers.

Authors:  Furong Qiu; Jian Jiang; Yueming Ma; Guangji Wang; Chenglu Gao; Xinfeng Zhang; Liang Zhang; Songcan Liu; Min He; Leilei Zhu; Yujie Ye; Qiuye Li; Ping Miao
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.